Related Experiment Videos
Breast conservation surgery using nipple-areolar resection for central breast cancers
Christopher M Pezzi1, John S Kukora, Isabelle M Audet
1Department of Surgery, Abington Memorial Hospital, Abington, Pa 19001, USA. chmario@aol.com
Archives of Surgery (Chicago, Ill. : 1960)
|January 14, 2004
Summary
Nipple-areolar complex resection for central breast cancers offers good cosmetic results and low recurrence rates. This breast conservation surgery extends options for patients with nipple or areola involvement, including Paget disease.
Area of Science:
- Oncology
- Surgical Oncology
- Breast Cancer Surgery
Background:
- Breast conservation surgery (BCS) is a standard treatment for breast cancer.
- Traditionally, central breast cancers involving the nipple-areolar complex (NAC) were excluded from BCS.
- Nipple-areolar complex resection (NACR) is a surgical option for specific central breast cancers.
Purpose of the Study:
- To evaluate the oncologic safety and cosmetic outcomes of NACR for central breast cancers involving the NAC.
- To determine if BCS indications can be safely extended to include these cases.
- To assess recurrence rates and survival following NACR and radiation therapy.
Main Methods:
- Retrospective review of 15 patients (aged 46-88) who underwent NACR for central breast cancers involving the NAC.
- Interventions included NAC resection and postoperative radiation therapy.
- Outcomes assessed via patient questionnaires and medical record review, focusing on recurrence, survival, and cosmesis.
Main Results:
- 15 patients with central breast cancers involving the NAC (10 subareolar, 5 Paget disease) underwent NACR.
- Average tumor size was 1.6 cm.
- With a mean follow-up of 32 months, only 1 recurrence (7%) was observed, with all patients alive and disease-free. Cosmetic results were satisfactory to excellent.
Conclusions:
- NACR is a safe and effective oncologic procedure for central breast cancers involving the NAC.
- This approach extends BCS indications, offering good cosmetic outcomes and low recurrence rates.
- NACR is a viable option for central subareolar cancers and Paget disease of the nipple.